Immuno-metabolic profile of patients with psychotic disorders and metabolic syndrome. Results from the FACE-SZ cohort.
Brain, Behavior, & Immunity - Health. 2022-07-01; 22: 100436
DOI: 10.1016/j.bbih.2022.100436
Read on PubMed
1. Brain Behav Immun Health. 2022 Mar 29;22:100436. doi:
10.1016/j.bbih.2022.100436. eCollection 2022 Jul.
Immuno-metabolic profile of patients with psychotic disorders and metabolic
syndrome. Results from the FACE-SZ cohort.
Foiselle M(1)(2)(3), Barbosa S(4), Godin O(1)(2)(3), Wu CL(2)(3), Boukouaci
W(2)(3), Andre M(3)(5), Aouizerate B(3)(6)(7), Berna F(3)(8), Barau C(9),
Capdevielle D(3)(5), Vidailhet P(3)(8), Chereau I(3)(10), Davidovic L(4), Dorey
JM(3)(11), Dubertret C(3)(12)(13), Dubreucq J(3)(14), Faget C(3)(15), Fond
G(3)(15), Leigner S(3)(14), Llorca PM(3)(9), Mallet J(3)(12)(13), Misdrahi
D(3)(16)(17), Martinuzzi E(4), Passerieux C(3)(18), Rey R(3)(11), Pignon
B(1)(2)(3), Urbach M(3)(18), Schürhoff F(1)(2)(3), Glaichenhaus N(4), Leboyer
M(1)(2)(3), Tamouza R(1)(2)(3); FACE-SZ (FondaMental Academic Centers of
Expertise for Schizophrenia) Groups.
Collaborators: Berna F, Haffen E, Leboyer M, Llorca PM, Schürhoff F, Barteau V,
Bensalem S, Godin O, Laouamri H, Souryis K, Leboyer M, Offerlin-Meyer I, Pignon
B, Schürhoff F, Szöke A, Aouizerate B, Deloge A, Misdrahi D, Vilà E, Blanc O,
Chéreau I, Denizot H, Honciuc RM, Lacelle D, Llorca PM, Pires S, Dubertret C,
Mallet J, Portalier C, Dubreucq J, Fluttaz C, Gabayet F, Roman C,
Chesnoy-Servanin G, D’Amato T, Dorey JM, Rey R, Vehier A, Lançon C, Faget C,
Metairie E, Peri P, Vaillant F, Boyer L, Fond G, Berna F, Vidailhet P,
Zinetti-Bertschy A, Capdevielle D, Yazbek H, Esselin S, Jarroir M, Passerieux C,
Urbach M.
Author information:
(1)Univ Paris Est Créteil, INSERM U955, IMRB, Translational NeuroPsychiatry
Laboratory, F-94010, Créteil, France.
(2)AP-HP, Hôpitaux Universitaires Henri Mondor, Département Médico-Universitaire
de Psychiatrie et d’Addictologie (DMU IMPACT), Fédération
Hospitalo-Universitaire de Médecine de Précision en Psychiatrie (FHU ADAPT),
F-94010, France.
(3)Fondation FondaMental, France.
(4)Université Côte d’Azur, Centre National de la Recherche Scientifique,
Institut de Pharmacologie Moléculaire et Cellulaire, Valbonne, France.
(5)Service Universitaire de Psychiatrie Adulte, Hôpital la Colombière, CHRU
Montpellier, Université Montpellier 1, Inserm 1061, Montpellier, France.
(6)Centre Hospitalier Charles Perrens, Université de Bordeaux, Bordeaux,
F-33076, France.
(7)INRAE, NutriNeuro, University of Bordeaux, U1286, Bordeaux, F-33076, France.
(8)Hôpitaux Universitaires de Strasbourg, Université de Strasbourg, INSERM
U1114, Fédération de Médecine Translationnelle de Strasbourg, Strasbourg,
France.
(9)APHP, Hôpital Henri Mondor, Plateforme de Ressources Biologiques, France.
(10)CHU Clermont-Ferrand, Department of Psychiatry, University of Clermont
Auvergne, EA 7280, Clermont-Ferrand, France.
(11)INSERM U1028, CNRS UMR5292, Centre de Recherche en Neurosciences de Lyon,
Université Claude Bernard Lyon 1, Equipe PSYR2, Centre Hospitalier Le Vinatier,
France.
(12)AP-HP, Groupe Hospitalo-Universitaire AP-HP Nord, service de Psychiatrie et
Addictologie, Hopital Louis Mourier, Colombes, France.
(13)Université de Paris INSERM UMR1266, Institute of Psychiatry and Neuroscience
of Paris, France.
(14)Centre Référent de Réhabilitation Psychosociale et de Remédiation Cognitive
(C3R), CH Alpes Isère, France.
(15)AP-HM, Aix-Marseille Univ, School of Medicine – La Timone Medical Campus, EA
3279, CEReSS – Health Service Research and Quality of Life Center, Marseille,
France.
(16)Department of Adult Psychiatry, Charles Perrens Hospital, Bordeaux, France.
(17)University of Bordeaux, CNRS UMR 5287-INCIA « Neuroimagerie et cognition
humaine », France.
(18)Service Universitaire de psychiatrie et d’addictologie du Centre Hospitalier
de Versailles, INSERM UMR1018, CESP, Team “DevPsy”, Université de Versailles
Saint-Quentin-en-Yvelines, Paris, Saclay, France.
BACKGROUND: Metabolic syndrome (MetS) is a highly prevalent and harmful medical
disorder often comorbid with psychosis where it can contribute to cardiovascular
complications. As immune dysfunction is a key shared component of both MetS and
schizophrenia (SZ), this study investigated the relationship between immune
alterations and MetS in patients with SZ, whilst controlling the impact of
confounding clinical characteristics including psychiatric symptoms and
comorbidities, history of childhood maltreatment and psychotropic treatments.
METHOD: A total of 310 patients meeting DSM-IV criteria for SZ or
schizoaffective disorders (SZA), with or without MetS, were systematically
assessed and included in the FondaMental Advanced Centers of Expertise for
Schizophrenia (FACE-SZ) cohort. Detailed clinical characteristics of patients,
including psychotic symptomatology, psychiatric comorbidities and history of
childhood maltreatment were recorded and the serum levels of 18 cytokines were
measured. A penalized regression method was performed to analyze associations
between inflammation and MetS, whilst controlling for confounding factors.
RESULTS: Of the total sample, 25% of patients had MetS. Eight cytokines were
above the lower limit of detection (LLOD) in more than 90% of the samples and
retained in downstream analysis. Using a conservative Variable Inclusion
Probability (VIP) of 75%, we found that elevated levels of interleukin (IL)-6,
IL-7, IL-12/23 p40 and IL-16 and lower levels of tumor necrosis factor (TNF)-α
were associated with MetS. As for clinical variables, age, sex, body mass index
(BMI), diagnosis of SZ (not SZA), age at the first episode of psychosis (FEP),
alcohol abuse, current tobacco smoking, and treatment with antidepressants and
anxiolytics were all associated with MetS.
CONCLUSION: We have identified five cytokines associated with MetS in SZ
suggesting that patients with psychotic disorders and MetS are characterized by
a specific “immuno-metabolic” profile. This may help to design tailored
treatments for this subgroup of patients with both psychotic disorders and MetS,
taking one more step towards precision medicine in psychiatry.
© 2022 The Authors.
DOI: 10.1016/j.bbih.2022.100436
PMCID: PMC9034311
PMID: 35469211
Conflict of interest statement: All authors declare that they have no competing
interests.